KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Debt Repayments (2016 - 2024)

Pacira BioSciences (PCRX) has 8 years of Long-Term Debt Repayments data on record, last reported at -$182.4 million in Q4 2024.

  • For Q4 2024, Long-Term Debt Repayments changed N/A year-over-year to -$182.4 million; the TTM value through Sep 2024 reached $182.4 million, changed N/A, while the annual FY2024 figure was $8.6 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached -$182.4 million in Q4 2024 per PCRX's latest filing, down from $182.4 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $192.6 million in Q1 2022 and bottomed at -$182.4 million in Q4 2024.
  • Average Long-Term Debt Repayments over 3 years is $61.6 million, with a median of $106.2 million recorded in 2020.
  • The widest YoY moves for Long-Term Debt Repayments: up 52405.62% in 2020, down 52405.62% in 2020.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $176.8 million in 2020, then crashed by 79.84% to $35.6 million in 2022, then plummeted by 611.52% to -$182.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were -$182.4 million in Q4 2024, $182.4 million in Q3 2024, and $35.6 million in Q3 2022.